Valuation: Grace Therapeutics, Inc.

Market Cap 54.74M 38.58M 33.83M 31.18M 29.19M 3.64B 55.88M 375M 145M 1.8B 145M 142M 6.24B P/E 2027 *
-4.56x
P/E 2028 * -4.34x
Enterprise Value 54.74M 38.58M 33.83M 31.18M 29.19M 3.64B 55.88M 375M 145M 1.8B 145M 142M 6.24B EV / Sales 2027 *
-
EV / Sales 2028 * 6.99x
Free-Float
74.27%
Yield 2027 *
-
Yield 2028 * -
1 day+1.69%
1 week+6.19%
Current month-6.61%
1 month+1.69%
3 months-49.69%
6 months-29.41%
Current year-30.64%
1 week 2.24
Extreme 2.24
2.48
1 month 2.13
Extreme 2.13
2.71
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
30.24
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 04/04/2023
Director of Finance/CFO 54 05/01/2024
Chief Tech/Sci/R&D Officer 64 08/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 04/04/2023
Director/Board Member 59 10/10/2023
Date Insider Type Main position Quantity % Market Cap.
01-12Option

Director

10,000 0.0646%
01-12Option

Chairman

10,000 0.0646%
01-12Option

Director

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
+1.69%+6.19%-18.37%-26.32% 38.57M
+0.33%+1.37%+64.03%+119.11% 55.35B
+0.82%+15.05%+74.28%+86.70% 51.92B
-0.78%-1.23%-16.07%-16.69% 22.76B
+1.36%+7.67%+4.35%+433.25% 22.64B
-0.18%+7.20%+28.56%-12.48% 17.36B
-1.10%+4.00%+28.70%-34.51% 16.1B
-3.35%+8.96%+135.18%+294.38% 13.96B
+2.14%+6.10%+26.43%+179.96% 13.38B
+1.31%+0.53%+27.21% - 12.27B
Average +0.23%+4.12%+35.43%+113.71% 22.58B
Weighted average by Cap. +0.23%+5.29%+47.24%+123.04%

Financials

2027 *2028 *
Net sales - 7.83M 5.52M 4.84M 4.46M 4.18M 521M 8M 53.63M 20.75M 257M 20.73M 20.28M 893M
Net income -12.76M -8.99M -7.88M -7.27M -6.8M -848M -13.02M -87.35M -33.8M -419M -33.77M -33.03M -1.45B -20.46M -14.42M -12.65M -11.66M -10.91M -1.36B -20.89M -140M -54.21M -672M -54.16M -52.98M -2.33B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
26/06/26 $2.400 +1.27% 142,203
25/06/26 $2.370 +1.72% 228,288
24/06/26 $2.330 -2.51% 170,487
23/06/26 $2.390 +5.75% 395,355
22/06/26 $2.260 -5.04% 260,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.364CAD
Average target price
8.447CAD
Spread / Average Target
+151.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock